Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study for Treatment of Acne With Enhanced Microcyn(R) Hydrogel Formulation Jun 19, 2009
Oculus Innovative Sciences Reports FY 2009 Financial Results and Discusses Worldwide Revenue Growth Prospects Jun 11, 2009
FDA Clears Expanded Label Claim for Oculus Innovative Sciences' Lead Microcyn(R) Wound Care Product Jun 4, 2009
Oculus Innovative Sciences Announces Fiscal Fourth Quarter Financial Results and Corporate Update Release and Conference Call May 28, 2009
Oculus Innovative Sciences Reports Significant Increase in Sales of its Approved Microcyn(R) Product in Mexico as H1N1 Flu (Swine Flu) Spreads May 4, 2009
Oculus Innovative Sciences Reports Third Quarter Product Revenue Up 19% with a $2.6 Million Reduction in Operating Expenses Feb 12, 2009
Oculus Innovative Sciences to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference Feb 10, 2009
Oculus Innovative Sciences' Security Holders Exercise Rights or Invest in Company as Result of Recently Announced Strategic Investment by VetCure, Inc. Feb 9, 2009
Oculus Innovative Sciences Announces Fiscal Third Quarter Financial Results and Corporate Update Release and Conference Call Feb 9, 2009
